Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 209 for your search:
Cancer Type/Condition:
Brain tumor, adult: Glioblastoma
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Low-dose Temozolomide for 2 Weeks on Brain Tumor (Study P04602AM1)
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
P04602
, NCT00424554
2.
Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
MRC-BR12
, EU-20114, ISRCTN83176944, NCT00052455
3.
Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
65 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
CAN-NCIC-CE6
, EORTC-26062, EORTC-22061, CE6, SPRI-CAN-NCIC-CE.6, NCT00482677
4.
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
EMD 121974-011
, EORTC 26071-22072, NCT00689221
5.
Nimotuzumab in Adults With Glioblastoma Multiforma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
OSAG101-BSA05
, NCT00753246
6.
Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
60 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
LEONB-ET2005-006
, ET2005-006, LEONB-Nordic Glioma Adulte, INCA-RECF0031, EUDRACT-2006-003606-25, SPRI-LEONB-ET2005-006, NCT00820963
7.
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
RTOG-0825
, RTOG 0825, NCT00884741
8.
Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
IcmLCBT_301
, NCT00807027
9.
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
EF-14
, NCT00916409
10.
A Study of Avastin (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
BO21990
, 2008-006146-26, NCT00943826
11.
A Phase I/II Study of the Photon Radiosurgery System
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
2 to 32
Sponsor:
Other
Protocol IDs:
CNS 0201
, NCT00179907
12.
Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
CNS-09-0027
, NCT00250211
13.
GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UCSF-05103
, 05103, UCSF-H41995-27311-01, NCT00293423
14.
ZD6474 in Treating Patients With Recurrent or Progressive Gliomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-06-C-0063
, NCI-P6680, NCT00293566
15.
Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCCTG-N0572
, N0572, NCT00329719
16.
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
501007705
, NCT00301418
17.
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ABTC-05-02
, NABTC-05-02, NCT00335764
18.
Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
Eudract-2005-003911-63
, PEI 119/01, NCT00311857
19.
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ABTC-0504
, NABTT-0504, NABTT-0504, NCT00379080
20.
AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
021-003
, NCT00394628
21.
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
06-377
, IRUSZACT0018, NCT00441142
22.
Intracerebral Clysis in Treating Patients With Recurrent Primary Brain Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 120
Sponsor:
Other
Protocol IDs:
R01 CA 89395-01
, Topotecan, Brain Tumors, Intracerebral Clysis, NCT00452959
23.
Radiosurgery for Glioblastoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Over 65
Sponsor:
Other
Protocol IDs:
2006P-000464
, NCT00456612
24.
Hydroxychloroquine, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ABTC-0603
, NABTT-0603, 0603, NCT00486603
25.
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
UCLA-0604104
, OSI3781s, NCT00509431
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
